One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.1 Further data revealed that, in the case of the TNFα inhibitor infliximab, nearly three-quarters of PsA patients were on doses lower than recommended in international guidelines.2

In the first study, after 28 weeks of treatment one-third of PsA were found to have serum adalimumab trough concentrations below the 5 mg/L level shown to have an optimal effect. However, these low doses still showed reasonable efficacy1

In the second study, low dosing of infliximab in more than 70% of a population of Icelandic and Danish PsA patients did not seem to alter either treatment response or adherence to therapy2

PsA is a chronic inflammatory arthritis associated with psoriasis, which significantly impacts health-related quality of life, and may lead to severe, disabling joint damage.3 Psoriasis occurs in 1-3% of the population,4 with PsA occurring in up to 30% of those of cases.5

One third of PsA patients not receiving optimal dosing of adalimumab

Presenting the results of the Dutch study, lead author Mr. Erik Vogelzang of the Jan van Breemen Research Institute, Reade, Amsterdam, Netherlands reported that serum trough levels of adalimumab of 5- 8 mg/L appeared necessary to achieve the most optimal clinical benefit. Concentrations above 8 mg/L appeared to confer no additional benefit; however, concentrations of approximately 1.0 mg/L showed reasonable efficacy.1

"These results linking serum adalimumab trough concentrations to clinical response in PsA patients confirmed the findings from a previous study in RA patients," 6 said Mr. Erik Vogelzang.

"However, interestingly, of the 103 consecutive patients with PsA prescribed adalimumab, 36 (35%) appeared to be receiving less than optimal dosing, with a trough adalimumab concentration below 5 mg/L (the lowest point of this ideal dose range). A substantial group of PsA patients that use adalimumab are therefore not able to profit from its optimal ," Vogelzang concluded.

This was a prospective cohort study in which 103 consecutive patients diagnosed with PsA were treated with 40 mg adalimumab subcutaneously every other week. Adalimumab concentrations at 28 weeks of treatment were measured in serum trough samples, using an enzyme linked immunosorbent assay (ELISA). Clinical response was defined as a change in disease activity score in 28 joints (ΔDAS28) between baseline and week 28. At 28 weeks of treatment, serum trough concentrations ranged from 0.0 to 18.8 mg/L, with a mean of 7.2 mg/L. In 48 (47%), trough adalimumab concentrations exceeded the optimal threshold of 8 mg/L.

Low dosing of infliximab does not appear to alter treatment response or adherence

International guidelines recommend that patients with arthritis PsA prescribed the TNFα inhibitor infliximab should be dosed with 5 mg/kg bodyweight every 8th week. However, responses to lower doses have not been previously well documented.2

Dr Bente Glintborg of the Copenhagen Centre for Arthritis Research, and Centre for Rheumatology and Spine Diseases, Glostrup Hospital, Denmark presented the clinical outcomes in a large cohort of TNFα inhibitor-naïve PsA patients treated with infliximab, stratified by country (Denmark vs. Iceland), and by their dose regimen and escalation.

"More than 70% of Icelandic and Danish PsA patients treated with infliximab received sustained doses below the recommended 5 mg/kg every eight weeks," said Dr Glintborg. "Lower start doses did not appear to affect either drug adherence or response," she added. Thus, in clinical practise a low start infliximab dose with subsequent step up therapy seems to be an efficient strategy.

Danish patients received higher infliximab doses than Icelandic patients at baseline (median (IQR) 3.1 (3.0-3.8) mg/kg vs. 2.3 (2.1-2.9) mg/kg, p<0.05) and after 12 months (3.3 (3.0-4.5) mg/kg vs. 2.9 (2.2-3.5) mg/kg, p<0.0001). In Danish patients, the start dose was ≤3 mg/kg in 110 patients (29%), 3-5 mg/kg in 157(42%), ≥5 mg/kg in 38(10%) and unregistered in 71(19%). In Icelandic patients, the corresponding numbers were 64 (74%), 17 (27%), 0 (0%) and 5 (6%). Patients with higher body weight received lower infliximab doses per kg.

"Despite these important differences between Icelandic and Danish patients, they were found to have similar one-year response rates," said Dr Glintborg. After 12 months, 58% of Danish and 66% of Icelandic patients maintained treatment. In univariate analyses stratified by country, the time until dose escalation, ACR20/50/70 or EULAR-response rates, drug adherence and one-year's disease activity were independent of the baseline dose of infliximab," Dr Glintborg explained.

This was an observational cohort study based on the nationwide DANBIO and ICEBIO registries. Among the 1,589 patients identified in the two registries, 462 patients (29%, 376 Danish, 86 Icelandic) received treatment with infliximab. Dose escalation was defined as an increase in either the dose and/or frequency. Treatment response was evaluated by ACR20/50/70 and EULAR-good-response after six months of treatment and disease activity after one year of treatment. Kaplan-Meier plots and regression analyses were performed to analyse adherence to treatment and to identify predictors of treatment response and adherence.

More information: Abstract Numbers: OP0074 and OP0075

Notes:

1 Vogelzang E et al. A concentration-effect curve of adalimumab in patients with psoriatic arthritis. EULAR 2014; Paris: Abstract OP0074
2 Glintborg B et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with PsA. Results from the nationwide registries DANBIO and ICEBIO. EULAR; Paris: Abstract OP0075
3 Gladman DD. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64:ii14-ii17
4 Ayala F. Clinical presentation of psoriasis. Reumatismo 2007; 59(Suppl 1):40-5
5 Zachariae H . Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7
6 Pouw MF, Krieckaert CL, Nurmo

add to favorites email to friend print save as pdf

Related Stories

Adalimumab relieves hidradenitis suppurativa

Dec 18, 2012

(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment ...

High doses of saw palmetto don't impact serum PSA

Feb 08, 2013

(HealthDay)—Compared with placebo, saw palmetto, even at a dose as high as 960 mg, does not affect serum prostate-specific antigen (PSA) levels in men with lower urinary tract symptoms, according to research ...

Recommended for you

ACR: Most hospitalizations for gout are preventable

Nov 18, 2014

(HealthDay)—Most hospitalizations for a primary diagnosis of gout are preventable, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in ...

TNF inhibitors may increase cancer risk in the eye

Nov 17, 2014

One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.